Quick Facts: Therapeutic Domains

• May provide relief from occasional heartburn.
• Used for the management of acid indigestion.
• May help address gas and associated bloating.
• Contributes to the mitigation of stomach discomfort related to excess acid.

---

Digene Tab is an over-the-counter (OTC) antacid formulation intended to offer symptomatic management for various digestive issues linked to excess stomach acid. The product is used to relieve the burning sensation of heartburn and can help manage acid indigestion and related sour stomach conditions. The components of this formulation are commonly combined to address acid-related discomfort in the upper digestive tract.

The antacid combination is designed to neutralize excess gastric acid, which may help mitigate symptoms of stomach discomfort and irritation of the stomach lining. Additionally, the inclusion of an anti-gas component may help reduce the presence of excess gas and bloating by allowing gas bubbles to combine and pass more easily. Use of antacids is primarily restricted to relieving mild intermittent gastroesophageal reflux disease (GERD) symptoms.

For persistent, recurrent, or severe symptoms, consultation with a healthcare professional is necessary to determine if an underlying condition requires a prescribed treatment plan. This product is suitable for temporary and occasional relief as directed by a healthcare provider.

Who Can and Cannot Use Digene Tab Tablet?

The population eligibility for using this antacid and antiflatulent combination is strictly defined by regulatory documents, which list specific contraindications and use restrictions. The medicine is primarily intended for Adults and Adolescents 12 years and over.

Contraindicated Populations (Must Not Use)

• Patients with Kidney Failure or Severe Renal Impairment due to the risk of accumulating aluminum and magnesium.
• Individuals with known hypersensitivity or allergy to Aluminium Hydroxide, Magnesium Hydroxide, Simethicone, or any excipients.
• Patients diagnosed with specific hereditary metabolic disorders, such as Hereditary Fructose Intolerance.

Age-Based and Conditional Restrictions

Population	Regulatory Status
Children under 12	Not Recommended without medical advice; safety and efficacy are not established for unsupervised use.
Moderate Kidney Disease	Use is restricted; patients must consult a healthcare professional before use.
Pregnancy/Lactation	Ask a healthcare professional before use; limited systemic absorption is noted, but consultation is required.

Use is also cautioned in severely debilitated patients and those with conditions like intestinal obstruction. Patients on a magnesium-restricted or low-phosphorus diet should seek professional medical advice before taking this medication.

Interactions with other medicines and products

Exposure-Modifying Substances

The official interaction profile for this antacid combination is defined by pharmacokinetic interactions detailed in regulatory documents. These interactions result from the ability of Aluminium and Magnesium ions to physically bind to certain co-administered medicines, or by altering the pH of the stomach. Co-administration can significantly decrease the systemic exposure and subsequent plasma concentrations of agents such as tetracycline antibiotics, fluoroquinolone antibiotics, iron salts, and specific pH-sensitive prescription drugs including Alendronate and Cabotegravir. Conversely, the product may increase the plasma levels of basic drugs like Amphetamine and related sympathomimetic amines by raising urinary pH and reducing their renal clearance.

Administration Restrictions

Restriction Type	Official Requirement
Timing Separation	Dosing must be separated for many sensitive oral medicines (e.g., antibiotics, bisphosphonates) that are subject to reduced absorption. Regulatory information generally requires administering the antacid at least two hours apart from these agents to maintain appropriate therapeutic exposure.
Drug-Substance Restriction	Co-administration with Citrates (found in certain foods, beverages, or supplements) is formally restricted in specific patients, as citrates significantly increase the systemic absorption of aluminum, leading to a heightened risk of intoxication.
Population Caution	Patients with Renal Impairment are at heightened risk of accumulation of the active ingredients. This risk is specifically noted as major when co-administering the antacid with Citrate-containing products in this population.

Direct Gastric Acid Neutralization

This domain involves the basic compounds Aluminum Hydroxide and Magnesium Hydroxide. They engage a pathway effect of direct chemical reaction with the hydrogen ions ( H^+) of hydrochloric acid in the gastric lumen, yielding water and neutral salts. This interaction causes a rapid increase in the gastric pH. The resulting modification to the acidic environment—an early molecular step—leads to the physiological consequence of stabilizing the low pH range. This physicochemical action reduces the H^+ concentration, thereby decreasing the corrosivity of the gastric fluid.

---

Antifoaming and Gas Regulation

This domain is managed by Simethicone, a surface-active agent that acts physically within the gastrointestinal system. It modulates pathways associated with gas entrapment by lowering the surface tension of gas bubbles trapped in the stomach and intestines. This action promotes the coalescence of smaller, dispersed gas bubbles into larger agglomerations, permitting the release of gas into the surrounding lumen. This physicochemical mechanism facilitates a reduction in luminal distension through the physical modification and dispersal of gaseous pockets.

How to Use Digene Tab Tablet

This section describes the administration principles and standardized dosing regimen for Digene Chewable Tablets.

---

The established route of administration for this formulation is oral, meaning the tablet is taken by mouth. It is critical that the tablet be chewed or sucked thoroughly before being swallowed, as the chewable format is necessary for the active ingredients to begin neutralizing stomach acid immediately upon entry into the stomach. Swallowing the tablet whole is contrary to the intended administration method.

Standard Adult Dosing and Frequency

Administration of the medication is typically on an as-needed basis for the symptomatic relief of occasional discomfort. The standard single adult dose (for individuals over 12 years of age) is 2 to 4 tablets per instance of symptoms. Dosing is commonly specified for intake after meals and at bedtime, aligning with periods when acid reflux or indigestion symptoms are most likely to occur.

Procedural Constraints and Duration

To adhere to procedural safety limits, the administration must not exceed a maximum of 5 doses in a 24-hour period. This medication is explicitly designed for short-term, occasional use. Individuals are instructed to limit the use of the maximum dosage to no more than two weeks unless specifically directed by a healthcare professional. For children, the use is only permitted as advised by a physician, as the label recommends that individuals under 12 years of age should not self-administer.

Usage Constraint	Official Instruction
Route & Method	Oral, must be chewed thoroughly.
Timing	After meals and at bedtime.
Maximum Doses	5 doses in a 24-hour period.
Duration	Intended for short-term use only.

Digene Tab Tablet: Recent Clinical Evidence

---

Research Evidence for Occasional Heartburn and Acid Indigestion

Research into the antacid components (aluminium hydroxide and magnesium hydroxide) was evaluated in short-term Randomized Controlled Trials (RCTs). These studies research examined how quickly the ingredients could change stomach acidity. Trials reported measurable changes in gastric acidity that was associated with outcomes related to physical discomfort experienced during acid-related upset. Studies report patterns where changes in symptom intensity were observed in some studies within minutes after taking a single dose. Follow-up durations were limited, meaning long-term effects are not fully established regarding continuous daily use.

---

Research Evidence for Bloating and Excess Gas

The antiflatulent component, Simethicone, was studied for its role in symptoms like abdominal pressure and flatulence. This ingredient was evaluated in RCTs exploring short-term changes in these symptoms, with research focused on patient-reported outcomes describing perceived discomfort. Findings describe patterns observed in the studies where the antiflatulent component was observed in reducing the surface tension of gas bubbles. However, evidence quality varies, and comparative evidence is lacking to definitively show a superior pattern of symptom resolution when compared against simple observation.

---

Combination Studies and Research Gaps

Studies explored the combination effects through comparative pharmacokinetic (PK) trials, which focused on the formulation's Acid Neutralizing Capacity (ANC). The evidence was observed in some studies to provide a simultaneous focus on both chemical irritation from acid and physical discomfort from gas. The core evidence base results apply only to the populations studied (primarily adults). Data for certain groups, such as older adults with specific comorbid conditions, remain insufficient. Overall, the evidence base is limited by short follow-up durations, and the added symptomatic value of the antiflatulent component remains to be fully established in every scenario.

Key Studies & References

1. Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (NICE Guideline CG184)

Common questions about Digene Tab Tablet (FAQ)

Q: Can I drink alcohol while taking this medicine?

A: Official regulatory information advises caution when this medicine is used by a person who consumes substantial quantities of alcohol or has a history of liver disease. This is because the medication is associated with a risk of liver enzyme abnormalities. This indicates that high alcohol intake may potentially increase the risk.

Q: Does this medication make you sleepy or affect driving?

A: Regulatory information lists Central Nervous System (CNS) toxicity as a potential warning associated with this class of medication, and trouble sleeping is noted as a common side effect. Due to the listed potential for Central Nervous System effects, caution may be warranted regarding activities that require full mental alertness.

Q: Is this medicine safe for children 2 years old?

A: The official product labeling indicates this medication is not indicated for patients below the age of 10 years. The indication for use in pediatric patients begins at 10 years of age for certain types of hypercholesterolemia, according to the official label.

Q: How long do I have to take this medication?

A: According to the regulatory text, the therapeutic response to this medication is generally maintained during chronic therapy. The dose is typically adjusted based on individual response and the goal of therapy, with lipid levels assessed as early as 4 weeks after starting or adjusting the dose. The length of treatment is a decision made by a healthcare professional based on individual therapeutic goals.

Q: Are there any foods or drinks I should avoid while taking this?

A: Official product information advises that the concomitant intake of large quantities of grapefruit juice (specifically more than 1.2 liters daily) is not recommended. This is due to a potential increase in the risk of muscle injury when high amounts of grapefruit juice are consumed with the medication.

Q: Does this medicine affect my sugar levels?

A: Official warnings and precautions for this class of medicine (statins) state that increases in HbA1c and fasting serum glucose levels have been reported. Therefore, the official warnings highlight the potential for the medication to influence blood sugar-related measurements.

The official storage and disposal guidelines for Digene Tab Tablet are based on regulatory requirements for combination antacids and antiflatulents, focusing on maintaining stability and ensuring public safety.

Official Storage Requirements

Requirement	Constraint/Rule
Temperature	Store at room temperature, typically 20 C to 25 C (68 F to 77 F); protect from freezing and excessive heat [NIH DailyMed].
Protection	Keep in a cool, dry place, protected from moisture and direct sunlight (e.g., avoid bathroom storage) [MedlinePlus].
Packaging	Keep the product in the original container and ensure the cap or lid is tightly closed [NIH DailyMed].
Child Safety	Mandatory requirement to keep the product out of the sight and reach of children [MedlinePlus].

Official Disposal Requirements

Disposal Method: The preferred method for unused or expired tablets is to use a drug take-back location or mail-back program [FDA].

Environmental Rule: If take-back is unavailable, the product must not be flushed down the toilet or disposed of in wastewater. Instead, mix the tablets with an undesirable substance (like coffee grounds) and seal the mixture in a bag before placing it in the household trash [FDA].